P53 expression as a prognostic factor in upper urinary tract urothelial carcinoma: A systematic review and meta-analysis

Urologia Internationalis

Volumn 94, Issue 1, 2015, Pages 50-57

  Lee, Joo Yong ^a   Cho, Kang Su ^a   Diaz, Richilda Red ^a   Choi, Young Deuk ^a,b   Choi, Hong Yong ^c  

^a Urological Science Institute   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Hanyang University Guri Hospital   (South Korea)

Author keywords

Kidney neoplasms; Meta analysis; p53 genes; Transitional cell carcinoma; Ureteral neoplasms

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; FOLLOW UP; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; UPPER URINARY TRACT UROTHELIAL CARCINOMA; URINARY TRACT CARCINOMA; CARCINOMA; CHEMISTRY; CHI SQUARE DISTRIBUTION; FEMALE; MALE; PATHOLOGY; PREDICTIVE VALUE; RISK; RISK FACTOR; SEX DIFFERENCE; UPREGULATION; URINARY TRACT TUMOR; UROTHELIUM;

CARCINOMA; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84923376338     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000360227     Document Type: Review

References (30)

1. Bishop JM: Molecular themes in oncogenesis. Cell 1991; 64: 235-248.
2. Sidransky D, Messing E: Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am 1992; 19: 629-639.
3. Choi YD, Park JA, Cho NH, Yang WJ, Cho KS, Lee HY, Hong SJ: Expression of p53 and p73 genes in human transitional cell carcinoma of the bladder. Korean J Urol 2004; 45: 1209-1214.
4. Lane DP: p53, guardian of the genome. Nature 1992; 358: 15-16.
5. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327.
6. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
7. Horowitz JM: Regulation of transcription by the retinoblastoma protein. Genes Chromosomes Cancer 1993; 6: 124-131.
8. Kwak DY, Ha JY, Chang HS, Choi MS, Park CH, Kim CI: Clinical implications of the expression of survivin and p53 in superficial transitional cell carcinoma of the bladder. Korean J Urol 2009; 50: 12-17.
9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097.
10. Keaney M, Lorimer AR: Auditing the implementation of SIGN (Scottish Intercollegiate Guidelines Network) clinical guidelines. Int J Health Care Qual Assur Inc Leadersh Health Serv 1999; 12: 314-317.
11. Flay BR, Biglan A, Boruch RF, Castro FG, Gottfredson D, Kellam S, Moscicki EK, Schinke S, Valentine JC, Ji P: Standards of evidence: criteria for efficacy, effectiveness and dissemination. Prev Sci 2005; 6: 151-175.
12. Kumpfer KL, Alvarado R: Family-strengthening approaches for the prevention of youth problem behaviors. Am Psychol 2003; 58: 457-465.
13. Broening S, Kumpfer K, Kruse K, Sack PM, Schaunig-Busch I, Ruths S, Moesgen D, Pflug E, Klein M, Thomasius R: Selective prevention programs for children from substanceaffected families: a comprehensive systematic review. Subst Abuse Treat Prev Policy 2012; 7: 23.
14. Hashimoto H, Sue Y, Saga Y, Tokumitsu M, Yachiku S: Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 2000; 7: 457-463.
15. Park S, Hong B, Kim Y, Kim CS, Ahn H: Prognostic factors for survival in the transitional cell carcinoma of the upper urinary tract. Korean J Urol 2003; 44: 1087-1092.
16. Shinohara M, Okazawa A, Suzuki M, Itakura H, Munakata A, Kinoshita K: Clinical investigation of renal pelvic and ureteral cancer with special reference to adjuvant chemotherapy. Nihon Hinyokika Gakkai Zasshi 1995; 86: 1375-1382.
17. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998; 52: 594-601.
18. Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011; 59: 584-594.
19. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX: p53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005; 6: 678-686.
20. Terrell RB, Cheville JC, See WA, Cohen MB: Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. J Urol 1995; 154: 1342-1347.
21. Nakanishi K, Kawai T, Torikata C: Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum Pathol 1996; 27: 1336-1340.
22. Jinza S, Takano Y, Iki M, Noguchi S, Masuda M: Prognostic significance of p53 protein overexpression in transitional cell carcinoma of the renal pelvis and ureter. Urol Int 1998; 60: 147-151.
23. Bringuier PP, McCredie M, Sauter G, Bilous M, Stewart J, Mihatsch MJ, Kleihues P, Ohgaki H: Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogenmetabolising enzymes. Int J Cancer 1998; 79: 531-536.
24. Watanabe J, Nishiyama H, Kawanishi H, Ito M, Kamoto T, Ogawa O: Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors. J Urol 2005; 174: 73-75.
25. Jeong IG, Kim SH, Jeon HG, Kim BH, Moon KC, Lee SE, Lee E: Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol 2009; 40: 668-677.
26. Ku JH, Byun SS, Jeong H, Kwak C, Kim HH, Lee SE: The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 2013; 11: 221-228.
27. Mitchell S, Mayer E, Patel A: Expression of p53 in upper urinary tract urothelial carcinoma. Nat Rev Urol 2011; 8: 516-522.
28. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM: The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 2003; 169: 1219-1228.
29. Furihata M, Yamasaki I, Ohtsuki Y, Sonobe H, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N: p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. Int J Cancer 1995; 64: 298-303.
30. Kang TW, Lee JG, Jung SI, Choi YD, Choi C, Kwon DD, Park K, Ryu SB, Park YI: A study of microsatellite instability of upper urinary tract transitional cell carcinoma. Korean J Urol 2006; 47: 1269-1277.